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Background: Alzheimer’s disease (AD) is a major cognitive disorder classified as a common type of dementia. Magnetic resonance
imaging (MRI) is the most practical method for diagnostic purposes in AD. The aim of the study was to determine the volume of the
hippocampus and intracranial structures in AD using MRI.
Methods: A total of 102 patients with AD were classified based on the mini mental test scores as early, moderate, and advanced stage.
The control group included 35 healthy subjects. MRI were compared between the patients and control groups based on the calculations
made utilizing volBrain software. Intracranial volumetric parameters were also compared between the three stages of AD.
Results: The white matter volumes, total hippocampus, total cerebrum, right cerebrum, left cerebrum, truncus encephalic, total nucleus
caudatus and total corpus amygdaloideum were significantly increased in the AD. The white matter volumes, right hippocampus,
left hippocampus, total cerebrum, left cerebrum, and right cerebellum were significantly increased in the patients in the early stage
compared to the patients in the advanced stage AD.
Conclusion: The most efficient volumetric study in AD could be performed by obtaining long-term periodic morphometric data of an
early diagnosed and regularly followed-up patient population.
Key words: Alzheimer’s disease, dementia, hippocampus, white matter, volumetric analysis

1. Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative
disease accounting for 60%–80% of dementia diseases.
Although the cause has not been determined exactly, age is
the most important risk factor in the development of AD.
The incidence of AD is 0.4% in individuals over 65 years
old and 7.6% in those aged over 85 years. New AD cases
are reported by 0.4% in people aged under 75 years, 3.2%
in those aged between 75–84 years and 7.6% in individuals
over 85 years old annually [1]. The global incidence of AD
is estimated to exceed 50% in individuals aged over 65
years by 2050 [2]. Therefore, AD is expected to be among
the most hazardous health problems in the forthcoming
years.
The diagnosis of AD is established according to the
criteria of the National Institute of Neurological and
Communicative Disorders and Stroke and AD and
Related Disorders Association (NINCDS-ADRDA) and
The Diagnostic and Statistical Manual of Mental Disorders
(DSM) handbook [3]. In order to diagnose and follow-up

AD, it is necessary to have both clinical knowledge and the
characteristics of the disease course [4].
Numerous imaging methods are used for diagnostic
purposes regarding AD today, although magnetic
resonance imaging (MRI) is the most practical and easy
to access method for this purpose. In addition, it is also
possible to diagnose and treat neurodegenerative diseases
using MRI [5,6].
According to histological studies, the hippocampus
is susceptible to AD disease pathology and is severely
damaged when clinical symptoms first appear [7].
Therefore, the hippocampus is the primary target of
MRI studies in AD. In parallel to histological findings,
longitudinal MRI studies have found increased rates of
hippocampus volume loss compared to normal aging [8,9]
and mild cognitive impairment [10] in AD compared to
normal aging.
Many studies have mentioned temporal and spatial
changes in the white matter occurring in the course AD
[11,12]. An abnormal white matter volume is associated
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with poor cognitive performance in AD independently of
the cortical gray matter volume [12]. On the other hand,
cerebral degeneration studies on patients with AD have
shown pathological features in the cortical gray matter
[13]. Therefore, cognitive dysfunction may be experienced
in patients with AD as a result of changes in white or gray
matter.
The objective of this study was to determine
hippocampus volumes, substantia alba hyperintensities
the volumes of other intracranial structures in AD. For
this purpose, these structures were compared between the
patients with three stages of AD and healthy subjects using
volBrain (Manjón ve Coupé 2006) software.

diseases, degenerative diseases such as Parkinson diseases,
Amyotrophic lateral sclerosis, and essential tremor, and
those with primary or metastatic cerebral cancer.

2. Material and method
At first, the study protocol was approved by the Necmettin
Erbakan University Meram Medical Faculty Ethics
Committee for Research Outside Drugs and Medical
Devices with the decision (04-27-2018; 2018/1325). The
necessary permission to conduct the study was received
from the University of Health Sciences, Ümraniye Training
and Research Hospital Management.
2.1. Patients with AD
Demographic features and MRI data of patients presenting
to the neurology outpatient clinic of our hospital with the
complaint of forgetfulness, aged over 50 years, who were
at least primary school graduate and diagnosed with AD
by a neurologist according to the DSM-V (Diagnostic
and Statistical Manual of Mental disorders, 5th edition)
diagnostic criteria between 1st January 2017 and 31st
December 2018 were retrospectively evaluated. Patients’
age, gender, mini-mental test score, diseases, drugs used,
and MRI images were obtained from the patient files.
Data of patients with AD (n = 237) were screened.
Mini mental test date and cranial MRI date 74 patients
who were not compatible mini mental test date and cranial
MRI date, 22 patients who were not compatible with mini
mentally test scores and clinical findings, 39 patients who
were incompatible with exclusion criteria were removed
from the study. Finally, patients with AD (n = 102) were
included in the study. The patients were classified based
on the mini mental test scores as early-stage (31 patients),
moderate stage (41 patients), and advanced stage (30
patients).
A total of 35 patients who presented to the neurology
outpatient clinic with the complaint of nonspecific
headache, who had no complaints of forgetfulness and were
not diagnosed with AD based on the DSM-V diagnostic
criteria, and who were similar to the patient group in age
and gender were included as the control group.
The exclusion criteria included patients under 50
years old, illiterate patients, those with space-occupying
lesions in the brain, patients with cerebrovascular

2.3. volBrain programming
The volBrain program works fully automatically and
allows obtaining volumes of intracranial structures
without human interaction. volBrain provides volumetric
results in a practical, easy, and fast way. It was found by
Manjón and Coupé that volumes of the globus pallidus,
putamen, and nucleus caudatus were measured manually
and with various automatic methods, and volBrain
method has the highest correlation with the manual
method which is currently accepted as the gold standard
[14]. There are studies that have shown a high correlation
between volBrain and manual method which is measured
basal ganglia volumes in the literature to compare similar
studies [15]. A sample volumetry report of an early-stage
AD patient obtained from the volBrain is shown in Figure
1. Figure 2, Figure 3, and Figure 4 show volumetric report
samples of the moderate stage, advanced stage, and control
patients, respectively.
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2.2. MRI examination of patients
MRI examinations were performed in the radiology clinic
of our hospital using 1.5 Tesla GE optima (Waukesha USA)
head coil MRI device. T1 weighted MRBravo sequence
was set as axial, repetition time (TR) = 1800 ms, echo time
(TE) = 3.18 ms, FOV = 200 mm2, matrix: 224 × 224 and
slice thickness = 1mm. We evaluated the data of our study
with MRI for T1 weighted images according to volBrain
(http://volbrain.upv.es) online volumetric measurement
technique as an open-source.

2.4. Mini mental state examination (MMSE) test
Mini mental state examination (MMSE) test was developed
by Folstein and colleagues in 1975 for dementia screening
and is still the most used test today [16]. Total MMSE
score consists of 30 points with 10 points measuring
orientation to time and place, 3 points registration, 3
points recall, 5 points attention, 8 points language and
1-point visuospatial functions. An MMSE score between
25–30 points is evaluated as normal and a score <25 as a
cognitive disorder. MMSE scores between 20–24 points
indicate early stage or mild AD, 10–19 points moderate
stage AD, and 0–9 points advanced stage AD.
2.5. Statistical analysis
Data obtained from the study were statistically analysed
using SPSS version 23.0 (Statistical Package for Social
Sciences, SPSS Inc., Chicago, IL, USA). In the data analysis,
demographic features and parameters of the patients were
expressed as descriptive statistics. Comparison between
the groups was made with t-test and ANOVA, and LSD
test among the post-hoc tests. The relationship of the
parameters with age and MMSE scores was evaluated with
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volBrain Volumetry Report. version 1.0 release 04-03-2015
Patient ID
job160725

Sex
Male
Volume (cm3 /%)
360.11 (27.13%)
749.52 (56.48%)
217.51 (16.39%)
1109.63 (83.61%)
1327.14 (100.00%)

Tissue type
White Matter (WM)
Grey Matter (GM)
Cerebro Spinal Fluid (CSF)
Brain (WM + GM)
Intracranial Cavity (IC)
Structure
Cerebrum

Total (cm3 /%)
964.80 (72.70%)
[64.34, 74.47]

Age
70

Image information
Orientation
radiological
Scale factor
0.71
SNR
17.06

[28.44, 40.69]
[39.81, 51.12]
[14.65, 25.29]
[74.71, 85.35]

Right (cm3 /%)
484.80 (36.53%)
[32.19, 37.40]

Report Date
07-Sep-2019

Left (cm3 /%)
480.00 (36.17%)
[32.12, 37.11]

GM
642.46
(48.41%)

WM
322.34
(24.29%)

GM
321.51
(24.23%)

WM
163.28
(12.30%)

GM
320.95
(24.18%)

WM
159.06
(11.98%)

[33.46, 42.99]

[25.78, 36.59]

[16.73, 21.51]

[12.91, 18.43]

[16.72, 21.49]

[12.85, 18.17]

Total (cm3 /%)
124.00 (9.34%)
[7.68, 10.24]

Cerebelum

Right (cm3 /%)
61.60 (4.64%)
[3.82, 5.15]

Left (cm3 /%)
62.40 (4.70%)
[3.85, 5.11]

Asym.(%)
0.9941
[-1.19, 2.21]

Asym.(%)
-1.2761
[-4.93, 4.88]

GM
97.75
(7.37%)

WM
26.25
(1.98%)

GM
46.90
(3.53%)

WM
14.70
(1.11%)

GM
50.85
(3.83%)

WM
11.54
(0.87%)

[5.56, 8.23]

[1.21, 2.92]

[2.72, 4.10]

[0.62, 1.52]

[2.82, 4.14]

[0.59, 1.41]

Total (cm3 /%)
20.91 (1.58%) [1.41, 1.91]

Brainstem

Structure
Lateral ventricles

Total (cm3 /%)
24.65 (1.86%)

Right (cm3 /%)
11.19 (0.84%)

Left (cm3 /%)
13.46 (1.01%)

[0.79, 3.22]

[0.36, 1.64]

[0.38, 1.64]

[-64.3667, 59.82]

Caudate

4.60 (0.35%)

2.35 (0.18%)

2.25 (0.17%)

4.7332

[0.36, 0.55]

[0.18, 0.28]

[0.17, 0.27]

[-5.2041, 9.79]

Putamen

6.96 (0.52%)

3.66 (0.28%)

3.30 (0.25%)

10.1431

[0.42, 0.63]

[0.21, 0.32]

[0.21, 0.32]

[-7.0087, 5.53]

Thalamus

7.62 (0.57%)

3.98 (0.30%)

3.64 (0.27%)

8.8760

[0.57, 0.78]

[0.28, 0.39]

[0.29, 0.40]

[-9.3104, 5.01]

Globus Pallidus

1.81 (0.14%)

0.84 (0.06%)

0.96 (0.07%)

-13.3123

[0.13, 0.20]

[0.06, 0.10]

[0.06, 0.10]

[-11.5906, 13.16]

Hippocampus

7.95 (0.60%)

3.97 (0.30%)

3.98 (0.30%)

-0.3045

[0.43, 0.62]

[0.22, 0.32]

[0.21, 0.31]

[-9.8785, 12.20]

Amygdala

0.91 (0.07%)

0.57 (0.04%)

0.35 (0.03%)

48.7919

[0.09, 0.14]

[0.04, 0.07]

[0.04, 0.07]

[-16.5101, 18.61]

Accumbens

0.15 (0.01%)

0.03 (0.00%)

0.12 (0.01%)

-121.1538

[0.02, 0.06]

[0.01, 0.03]

[0.01, 0.03]

[-39.7027, 13.86]

Asymmetry (%)
-18.3980

*All the volumes are presented in absolute value (measured in cm3 ) and in relative value (measured in relation to the ICV).
*The Asymmetry Index is calculated as the difference between right and left volumes divided by their mean (in percent).
*Values between brackets show expected limits (95%) of normalized volume in function of sex and age for each measure for reference purpose.
*Green and red values indicate that the volume is above or under the expected volume limits respectively.

Figure 1. The data obtained from an early-stage AD by volBrain volumetry report.
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volBrain Volumetry Report. version 1.0 release 04-03-2015
Patient ID
job160960

Sex
Male
Volume (cm3 /%)
327.84 (27.33%)
833.05 (69.46%)
38.47 (3.21%)
1160.89 (96.79%)
1199.37 (100.00%)

Tissue type
White Matter (WM)
Grey Matter (GM)
Cerebro Spinal Fluid (CSF)
Brain (WM + GM)
Intracranial Cavity (IC)
Structure
Cerebrum

Total (cm3 /%)
996.82 (83.11%)
[64.34, 74.47]

Age
70

Image information
Orientation
radiological
Scale factor
0.73
SNR
17.64

[28.44, 40.69]
[39.81, 51.12]
[14.65, 25.29]
[74.71, 85.35]

Right (cm3 /%)
500.29 (41.71%)
[32.19, 37.40]

Report Date
09-Sep-2019

Left (cm3 /%)
496.53 (41.40%)
[32.12, 37.11]

GM
703.92
(58.69%)

WM
292.90
(24.42%)

GM
348.66
(29.07%)

WM
151.63
(12.64%)

GM
355.27
(29.62%)

WM
141.27
(11.78%)

[33.46, 42.99]

[25.78, 36.59]

[16.73, 21.51]

[12.91, 18.43]

[16.72, 21.49]

[12.85, 18.17]

Total (cm3 /%)
138.59 (11.56%)
[7.68, 10.24]

Cerebelum

Right (cm3 /%)
66.49 (5.54%)
[3.82, 5.15]

Left (cm3 /%)
72.11 (6.01%)
[3.85, 5.11]

Asym.(%)
0.7531
[-1.19, 2.21]

Asym.(%)
-8.1097
[-4.93, 4.88]

GM
112.79
(9.40%)

WM
25.80
(2.15%)

GM
52.36
(4.37%)

WM
14.12
(1.18%)

GM
60.43
(5.04%)

WM
11.68
(0.97%)

[5.56, 8.23]

[1.21, 2.92]

[2.72, 4.10]

[0.62, 1.52]

[2.82, 4.14]

[0.59, 1.41]

Total (cm3 /%)
25.39 (2.12%) [1.41, 1.91]

Brainstem

Structure
Lateral ventricles

Total (cm3 /%)
13.10 (1.09%)

Right (cm3 /%)
7.12 (0.59%)

Left (cm3 /%)
5.97 (0.50%)

[0.79, 3.22]

[0.36, 1.64]

[0.38, 1.64]

[-64.3667, 59.82]

Caudate

6.93 (0.58%)

3.16 (0.26%)

3.77 (0.31%)

-17.4179

[0.36, 0.55]

[0.18, 0.28]

[0.17, 0.27]

[-5.2041, 9.79]

Putamen

7.55 (0.63%)

4.12 (0.34%)

3.43 (0.29%)

18.0796

[0.42, 0.63]

[0.21, 0.32]

[0.21, 0.32]

[-7.0087, 5.53]

Thalamus

8.33 (0.69%)

3.73 (0.31%)

4.60 (0.38%)

-20.8714

[0.57, 0.78]

[0.28, 0.39]

[0.29, 0.40]

[-9.3104, 5.01]

Globus Pallidus

1.61 (0.13%)

0.89 (0.07%)

0.73 (0.06%)

20.2268

[0.13, 0.20]

[0.06, 0.10]

[0.06, 0.10]

[-11.5906, 13.16]

Hippocampus

7.34 (0.61%)

3.94 (0.33%)

3.40 (0.28%)

14.9307

[0.43, 0.62]

[0.22, 0.32]

[0.21, 0.31]

[-9.8785, 12.20]

Amygdala

0.65 (0.05%)

0.37 (0.03%)

0.28 (0.02%)

28.4424

[0.09, 0.14]

[0.04, 0.07]

[0.04, 0.07]

[-16.5101, 18.61]

Accumbens

0.05 (0.00%)

0.00 (0.00%)

0.04 (0.00%)

-187.0968

[0.02, 0.06]

[0.01, 0.03]

[0.01, 0.03]

[-39.7027, 13.86]

Asymmetry (%)
17.6109

*All the volumes are presented in absolute value (measured in cm3 ) and in relative value (measured in relation to the ICV).
*The Asymmetry Index is calculated as the difference between right and left volumes divided by their mean (in percent).
*Values between brackets show expected limits (95%) of normalized volume in function of sex and age for each measure for reference purpose.
*Green and red values indicate that the volume is above or under the expected volume limits respectively.

Figure 2. The data obtained from a mild stage AD by volBrain volumetry report.
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volBrain Volumetry Report. version 1.0 release 04-03-2015
Patient ID
job160542

Sex
Female
Volume (cm3 /%)
365.41 (33.67%)
575.55 (53.03%)
144.38 (13.30%)
940.96 (86.70%)
1085.34 (100.00%)

Tissue type
White Matter (WM)
Grey Matter (GM)
Cerebro Spinal Fluid (CSF)
Brain (WM + GM)
Intracranial Cavity (IC)
Structure
Cerebrum

Total (cm3 /%)
805.38 (74.21%)
[66.31, 75.12]

Age
70

Image information
Orientation
radiological
Scale factor
0.62
SNR
17.51

[26.47, 40.87]
[42.08, 53.83]
[13.67, 23.07]
[76.93, 86.33]

Right (cm3 /%)
406.01 (37.41%)
[33.23, 37.70]

Report Date
06-Sep-2019

Left (cm3 /%)
399.37 (36.80%)
[33.02, 37.48]

GM
491.51
(45.29%)

WM
313.87
(28.92%)

GM
245.75
(22.64%)

WM
160.26
(14.77%)

GM
245.76
(22.64%)

WM
153.61
(14.15%)

[35.28, 45.31]

[24.15, 36.69]

[17.64, 22.68]

[12.13, 18.47]

[17.62, 22.65]

[12.01, 18.23]

Total (cm3 /%)
114.06 (10.51%)
[7.85, 10.58]

Cerebelum

Right (cm3 /%)
57.20 (5.27%)
[3.91, 5.29]

Left (cm3 /%)
56.85 (5.24%)
[3.92, 5.31]

Asym.(%)
1.6485
[-1.30, 2.48]

Asym.(%)
0.6100
[-4.59, 3.80]

GM
75.84
(6.99%)

WM
38.22
(3.52%)

GM
37.66
(3.47%)

WM
19.55
(1.80%)

GM
38.18
(3.52%)

WM
18.67
(1.72%)

[5.88, 8.64]

[1.01, 2.90]

[2.88, 4.29]

[0.51, 1.51]

[2.98, 4.37]

[0.49, 1.39]

Total (cm3 /%)
21.56 (1.99%) [1.42, 1.98]

Brainstem

Structure
Lateral ventricles

Total (cm3 /%)
15.70 (1.45%)

Right (cm3 /%)
8.03 (0.74%)

Left (cm3 /%)
7.67 (0.71%)

[0.56, 2.77]

[0.23, 1.36]

[0.28, 1.46]

[-65.7646, 48.17]

Caudate

3.96 (0.37%)

2.14 (0.20%)

1.82 (0.17%)

16.3087

[0.39, 0.59]

[0.19, 0.30]

[0.19, 0.30]

[-7.5563, 10.88]

Putamen

5.07 (0.47%)

2.49 (0.23%)

2.58 (0.24%)

-3.7938

[0.45, 0.66]

[0.22, 0.33]

[0.22, 0.33]

[-6.7497, 5.02]

Thalamus

6.95 (0.64%)

3.31 (0.31%)

3.64 (0.34%)

-9.3514

[0.62, 0.84]

[0.31, 0.42]

[0.31, 0.42]

[-7.0130, 5.02]

Globus Pallidus

1.32 (0.12%)

0.70 (0.06%)

0.61 (0.06%)

13.4705

[0.13, 0.21]

[0.06, 0.10]

[0.06, 0.11]

[-15.5433, 13.54]

Hippocampus

6.65 (0.61%)

2.89 (0.27%)

3.75 (0.35%)

-25.9627

[0.48, 0.65]

[0.24, 0.33]

[0.23, 0.32]

[-6.5379, 12.96]

Amygdala

0.27 (0.02%)

0.20 (0.02%)

0.06 (0.01%)

108.1206

[0.09, 0.14]

[0.05, 0.07]

[0.04, 0.07]

[-12.9383, 18.69]

Accumbens

0.14 (0.01%)

0.08 (0.01%)

0.06 (0.01%)

22.8311

[0.02, 0.06]

[0.01, 0.03]

[0.01, 0.03]

[-36.5243, 14.26]

Asymmetry (%)
4.5496

*All the volumes are presented in absolute value (measured in cm3 ) and in relative value (measured in relation to the ICV).
*The Asymmetry Index is calculated as the difference between right and left volumes divided by their mean (in percent).
*Values between brackets show expected limits (95%) of normalized volume in function of sex and age for each measure for reference purpose.
*Green and red values indicate that the volume is above or under the expected volume limits respectively.

Figure 3. The data obtained from an advanced stage AD by volBrain volumetry report.
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volBrain Volumetry Report. version 1.0 release 04-03-2015
Patient ID
job161713

Sex
Female
Volume (cm3 /%)
374.36 (27.00%)
695.39 (50.16%)
316.71 (22.84%)
1069.75 (77.16%)
1386.46 (100.00%)

Tissue type
White Matter (WM)
Grey Matter (GM)
Cerebro Spinal Fluid (CSF)
Brain (WM + GM)
Intracranial Cavity (IC)
Structure
Cerebrum

Total (cm3 /%)
911.53 (65.74%)
[66.31, 75.12]

Age
70

Image information
Orientation
radiological
Scale factor
0.94
SNR
17.77

[26.47, 40.87]
[42.08, 53.83]
[13.67, 23.07]
[76.93, 86.33]

Right (cm3 /%)
453.44 (32.70%)
[33.23, 37.70]

Report Date
13-Sep-2019

Left (cm3 /%)
458.09 (33.04%)
[33.02, 37.48]

GM
574.11
(41.41%)

WM
337.42
(24.34%)

GM
286.63
(20.67%)

WM
166.81
(12.03%)

GM
287.48
(20.73%)

WM
170.61
(12.31%)

[35.28, 45.31]

[24.15, 36.69]

[17.64, 22.68]

[12.13, 18.47]

[17.62, 22.65]

[12.01, 18.23]

Total (cm3 /%)
136.82 (9.87%)
[7.85, 10.58]

Cerebelum

Right (cm3 /%)
67.99 (4.90%)
[3.91, 5.29]

Left (cm3 /%)
68.83 (4.96%)
[3.92, 5.31]

Asym.(%)
-1.0200
[-1.30, 2.48]

Asym.(%)
-1.2159
[-4.59, 3.80]

GM
110.85
(7.99%)

WM
25.97
(1.87%)

GM
53.37
(3.85%)

WM
14.63
(1.05%)

GM
57.48
(4.15%)

WM
11.35
(0.82%)

[5.88, 8.64]

[1.01, 2.90]

[2.88, 4.29]

[0.51, 1.51]

[2.98, 4.37]

[0.49, 1.39]

Total (cm3 /%)
21.49 (1.55%) [1.42, 1.98]

Brainstem

Structure
Lateral ventricles

Total (cm3 /%)
55.87 (4.03%)

Right (cm3 /%)
25.44 (1.83%)

Left (cm3 /%)
30.43 (2.19%)

[0.56, 2.77]

[0.23, 1.36]

[0.28, 1.46]

[-65.7646, 48.17]

Caudate

5.07 (0.37%)

2.35 (0.17%)

2.71 (0.20%)

-14.3548

[0.39, 0.59]

[0.19, 0.30]

[0.19, 0.30]

[-7.5563, 10.88]

Putamen

7.06 (0.51%)

3.81 (0.27%)

3.25 (0.23%)

15.7417

[0.45, 0.66]

[0.22, 0.33]

[0.22, 0.33]

[-6.7497, 5.02]

Thalamus

7.58 (0.55%)

3.60 (0.26%)

3.98 (0.29%)

-9.9143

[0.62, 0.84]

[0.31, 0.42]

[0.31, 0.42]

[-7.0130, 5.02]

Globus Pallidus

2.30 (0.17%)

1.24 (0.09%)

1.06 (0.08%)

14.9816

[0.13, 0.21]

[0.06, 0.10]

[0.06, 0.11]

[-15.5433, 13.54]

Hippocampus

9.84 (0.71%)

5.14 (0.37%)

4.70 (0.34%)

8.8838

[0.48, 0.65]

[0.24, 0.33]

[0.23, 0.32]

[-6.5379, 12.96]

Amygdala

1.38 (0.10%)

0.60 (0.04%)

0.79 (0.06%)

-27.5580

[0.09, 0.14]

[0.05, 0.07]

[0.04, 0.07]

[-12.9383, 18.69]

Accumbens

0.10 (0.01%)

0.03 (0.00%)

0.07 (0.00%)

-67.9245

[0.02, 0.06]

[0.01, 0.03]

[0.01, 0.03]

[-36.5243, 14.26]

Asymmetry (%)
-17.8507

*All the volumes are presented in absolute value (measured in cm3 ) and in relative value (measured in relation to the ICV).
*The Asymmetry Index is calculated as the difference between right and left volumes divided by their mean (in percent).
*Values between brackets show expected limits (95%) of normalized volume in function of sex and age for each measure for reference purpose.
*Green and red values indicate that the volume is above or under the expected volume limits respectively.

Figure 4. The data obtained from a patient who is in the control group by volBrain volumetry report.
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Pearson’s correlation analysis. The results were evaluated at
a 95% confidence interval, p < 0.05 values were considered
statistically significant.
3. Results
A total of patients with AD (n = 102) were included in
the study with being at the early stage (n = 31), moderate
stage (n = 41), and advanced stages (n = 30). The control
group consisted of patients without AD (n = 35), 51.6%
of the patients at the first stage, 58.5% of the patients at
the moderate stage, 48.6% of the patients at the advanced
stage, and 48.6% of the patients in the control group
were females. No statistically significant difference was
observed between the groups in terms of gender (p > 0.05).
The mean age was significantly increased in the patients at
the advanced stage (81.43 ± 7.58) compared to those at the
early stage (73.00 ± 6.80), moderate stage (76.83 ± 8.53),
and the control group (74.03 ± 4.59) (for all p < 0.001). A
comparison of the cerebral volumes between AD patients
and the control group is given in Table 1.
The mean values were significantly increased in the
control group compared to the AD group in terms of all
parameters that showed statistical significance (for all p <
0.05). A comparison of the volumetric values between AD
stages is shown in Table 2.
The mean WhiMat, HipoR, HipoL, CerTWM,
CerRWM, CerLWM, and CreblR values were significantly
increased in the early stage compared to the advanced stage
(for all p < 0.05). Whereas, the mean IC, GreyMat, HipoT,
Bey, CerT, CerTGM, CerR, CerRGM, CerL, CerLGM, and
CreblR parameters were significantly increased in the early
stage compared to both the moderate and advanced stages
(for all p < 0.05).
According to the AD stages, MMSE results, it was
found that hippocampus volumes of the patients at the
same stage according to MMSE scores were different.
Patients with AD (n = 103) included in our study,
hippocampus total volumes of a male patient (76-year-old)
and a female patient (73-year-old) with the lowest MMSE
score (4 points) had similar hippocampus total volumes.
However, the mean WhiMat/HipoL, CerTWM/HipoL,
and CerLWM//HipoL volume ratios were significantly
increased in the AD group than in the control group as
hippocampus volumetric rates were compared between
the patients with AD and control group (for all p < 0.05).
According to stages of AD, the parameters studied
were compared, LatVentT/Hipot ratio was significantly
increased in the advanced stage group compared to the
patients at the early and moderate stages (p < 0.05). Again
LatVentT/HipoT ratio was significantly increased in all
stages of AD compared to the control group (p < 0.05).
According to comparison between genders, IC,
GreyMat, HipoR, SSS, Bey, CerT, CerTGM, CerR,

CerRGM, CerL, CerLGM, CreblR, Mesen, GlobPalT, IC/
ThalT, and CerTGM/HipoT parameters were significantly
higher in male than in female patients (p < 0.05).
The volumetric parameters of the patients at the early,
moderate, and advanced stages were compared according
to genders, no significant difference was found between
both sexes in terms of volume rates in the patients at the
early stage. In the moderate stage; the mean IC, GreyMat,
SSS, Bey, CerT, CerTGM, CerR, CerRGM, CerL, CerLGM,
CreblR, Mesen, GlobPalT, IC/HipoT, IC/HipoL, IC/CaudT,
CerT/HipoT, CerTGM/HipoT, CerTGM/HipoL, CerL/
HipoL, and CerLGM/HipoL parameters were significantly
increased in the male patients compared to the female
patients (for all p < 0.05). Again, in the advanced stage,
SSS, IC/CerTWM, and IC/CerLWM parameters were
significantly increased in the male than in the female
patients (p < 0.05).
There was a negative and weak correlation between
GreyMat, HipoT, HipoR, Bey, CerT, CerTGM, CerR,
CerL, CerLGM, ThalT, and AmygdT volumes and age (p
< 0.05; 0.33 < r <0.00); a negative moderate correlation
between CerRGM volume and age (p < 0.05; r = –0.35);
and a positive weak correlation between SSS and LatVentT
volumes and age (p < 0.05; r1 = 0.20, r2 = 0.22).
A positive weak correlation was found between IC,
WhiMat, GreyMat, HipoT, HipoR, HipoL, Bey, CerTGM,
CerTWM, CerRWM, CerLGM, CerLWM, CreblR, Mesen,
LatVentT, ThaltT, and CaudT volumes and MMSE (p <
0.05; 0.00 < r < 0.33) while there was a positive moderate
correlation between CerT, CerR, CerRGM, and CerL
volumes and MMSE (p < 0.05; r1= 0.38, r2 = 0.37, r3 =
0.34, r4 = 0.38), and a negative weak correlation between
LatVentT volume and MMSE (p < 0.05; r = –0.22).
Lastly, there was a negative moderate between AmygdT
volume and age in the patients at the early stage when
the correlation between age and MMSE was examined
according to the AD stages (p < 0.01; r = –0.393). No
significant correlations were found between the volumes,
age, and MMSE in the patients at the moderate and
advanced AD stages (both p > 0.05).
4. Discussion
More than 35 million people have been diagnosed with
AD worldwide and this number is expected to double in
the next 20 years [17]. AD is a type of dementia, which is
a progressive neurological cerebral disease. AD gradually
damages the brain by leading to memory loss, language
and behavioral problems, and difficulty in performing
basic daily tasks [18]. In the brain of a patient with AD,
the cortex and hippocampus shrink, damaging the regions
involved in thinking, planning, and recall.
Although AD is a gradual disease without known
treatment, early diagnosis is essential. Medical and
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Table 1. Comparison of the cerebral volumes between AD patients and the control
group. As defined: Intracranial cavity (IC), White matter (WhiMat), Grey matter
(GreyMat), Total hippocampus total (HipoT), Right hippocampus (HipoR), Left
hippocampus (HipoL), Central nervous system (SSS), Brain volume (Bey), Total
cerebrum (CerT), Grey matter of total cerebrum (CerTGM), White matter of total
cerebrum (CerTWM), Right cerebrum (CerR), Grey matter of right cerebrum
(CerRGM), White matter of right cerebrum (CerRWM), Left cerebrum (CerL), Grey
matter of left cerebrum (CerLGM), White matter of left cerebrum (CerLWM), Total
cerebellum (CerblT), Left cerebellum (CerblR), Right cerebellum (CerblL), Truncus
encephali (Mesen), Total nucleus caudatus (CaudT), Total putamen (PutamT), Total
globus pallidus (GlobPalT), Total corpus amygdaloideum (AmygdT).
AD

Control

p

IC

1329.36 ± 140.62

1357.28 ± 137.06

0.310

WhiMat

373.80 ± 47.72

423.94 ± 57.50

0.000

GreyMat

653.95 ± 73.61

682.18 ± 79.04

0.057

HipoT

7.31 ± 1.05

7.82 ± 1.19

0.019

HipoR

3.71± 0.59

3.97 ± 0.63

0.030

HipoL

3.66 ± 0.55

3.84 ± 0.64

0.097

SSS

295.69 ± 75.79

383.33 ± 525.08

0.332

Bey

1026.23 ± 138.17

1354.52 ± 1449.05

0.190

CerT

895.24 ±92.05

960.82 ± 96.63

0.000

CerTGM

562.14 ± 68.72

587.29 ± 65.46

0.061

CerTWM

333.10 ± 42.99

373.52 ± 49.79

0.000

CerR

448.70 ± 47.22

480.71 ± 48.18

0.001

CerRGM

280.48 ± 34.64

293.42 ± 31.80

0.054

CerRWM

168.22 ± 22.23

187.29 ± 23.86

0.000

CerL

446.54± 45.79

480.11 ± 48.75

0.000

CerLGM

281.66 ± 34.57

293.88 ± 33.97

0.072

CerLWM

164.88 ± 21.66

186.23 ± 26.77

0.000

CerblT

118.40 ± 16.12

123.85 ± 14.72

0.080

CreblR

59.36 ± 6.22

60.03 ± 11.65

0.667

CreblL

59.62 ± 8.19

62.07 ± 7.72

0.124

Mesen

20.47 ± 2.37

21.50 ± 3.21

0.046

LatVentT

34.42 ± 17.08

29.96 ± 18.12

0.192

ThalT

6.90 ± 1.21

7.20 ± 0.86

0.172

CaudT

4.72 ± 1.05

5.34 ± 0.72

0.001

PutamT

6.29 ± 1.08

6.41 ± 1.29

0.595

GlobPalT

1.73 ± 0.45

1.79 ± 0.68

0.647

AmygdT

0.77 ± 0.43

0.95 ± 0.36

0.030

neurological examinations involve separate semistructured
interviews with the patient and people who know
the patient. In addition, among the imaging methods
structural MRI measurements provide a large amount of
information in detecting and monitoring the evolution
of brain atrophy, which is considered an indicator of AD
development. Numerous researchers have used MRI to
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observe neuronal changes underlying clinical findings of
AD. These studies have reported significant volumetric
differences in the neocortex and hippocampus of AD
patients compared to healthy control subjects [19].
The accuracy of MRI in the diagnosis of AD is 87%. It
is possible to measure amygdala, parahippocampus, and
hippocampus volumes with MRI volumetric analysis. T1

YÜCEL et al. / Turk J Med Sci
Table 2. Comparison of the volumetric values between AD stages. As defined: Intracranial cavity (IC),
White matter (WhiMat), Grey matter (GreyMat), Total hippocampus total (HipoT), Right hippocampus
(HipoR), Left hippocampus (HipoL), Central nervous system (SSS), Brain volume (Bey), Total cerebrum
total (CerT), Grey matter of total cerebrum (CerTGM) , White matter of total cerebrum (CerTWM), Right
cerebrum (CerR), Grey matter of right cerebrum (CerRGM), White matter of right cerebrum (CerRWM),
Left Cerebrum (CerL), Grey matter of left cerebrum (CerLGM), White matter of left cerebrum (CerLWM),
Total cerebellum (CerblT), Left cerebellum (CerblR), Right cerebellum (CerblL), Truncus encephali
(Mesen), Total nucleus caudatus (CaudT), Total putamen (PutamT), Total globus pallidus (GlobPalT), Total
corpus amygdaloideum (AmygdT).
Early AD

Moderate AD

Advanced AD

p

IC

1390.02 ± 140.57

1308.76 ± 139.25

1294.85 ± 126.17

0.013

WhiMat

392.88 ± 53.83

372.27 ± 43.54

356.18 ± 40.04

0.009

GreyMat

687.58 ± 67.94

644.07 ± 58.93

632.72 ± 86.55

0.007

HipoT

7.77 ± 1.00

7.18 ± 1.03

7.01 ± 1.02

0.011

HipoR

3.92 ± 0.53

3.68 ± 0.59

3.54 ± 0.59

0.033

HipoL

3.84 ± 0.58

3.66 ± 0.46

3.46 ± 0.56

0.020

SSS

292.78 ± 74.85

290.39 ± 83.63

305.95 ± 66.34

0.676

Bey

1087.56 ± 89.19

1007.17 ± 175.77

988.90 ± 98.32

0.009

CerT

943.38 ± 80.61

889.51 ± 88.45

853.33 ± 87.50

0.000

CerTGM

595.20 ± 54.39

556.41 ± 66.39

535.81 ± 73.33

0.002

CerTWM

348.18 ± 47.55

333.10 ± 41.09

317.53 ± 35.70

0.019

CerR

473.04 ± 40.26

446.57 ± 44.20

426.47 ± 47.36

0.000

CerRGM

297.21 ± 27.05

278.05 ± 32.53

266.51 ± 38.12

0.002

CerRWM

175.83 ± 24.31

168.52 ± 21.60

159.96 ± 18.26

0.019

CerL

470.35 ± 41.22

442.94 ± 45.17

426.86 ± 41.30

0.001

CerLGM

297.99 ± 27.94

278.36 ± 34.41

269.30 ± 35.55

0.003

CerLWM

172.36 ± 23.66

164.59 ± 20.50

157.56 ± 18.96

0.027

CerblT

123.14 ± 10.10

116.74 ± 20.67

115.76 ± 13.24

0.141

CreblR

61.39 ± 5.21

59.17 ± 6.08

57.52 ± 6.91

0.049

CreblL

61.74 ± 5.28

59.01 ± 10.60

58.24 ± 6.53

0.207

Mesen

21.09 ± 2.38

20.47 ± 2.32

19.84 ± 2.32

0.119

LatVentT

31.57 ± 14.33

31.98 ± 17.76

40.69 ± 17.64

0.055

ThalT

7.26 ± 1.01

6.85 ± 1.35

6.59 ± 1.14

0.088

CaudT

4.86 ± 0.92

4.83 ± 1.00

4.43 ± 1.20

0.188

PutamT

6.32 ± 0.83

6.28 ± 1.21

6.27 ± 1.15

0.985

GlobPalT

1.73 ± 0.38

1.81 ± 0.55

1.64 ± 0.34

0.313

AmygdT

0.80 ± 0.36

0.83 ± 0.43

0.65 ± 0.48

0.211

weighted images are primarily used in the imaging of the
hippocampus [20]. The segmentation from MRI sections
of the hippocampus can be obtained both manually and
automatically [21]. The manual method is a limiting factor
in clinical practice as it is both time-consuming and can
vary from person to person [14].
In order to solve this problem, automatic multiple atlas
identification software such as volBrain (http://volbrain.
upv.es) is used [14]. Also in our study, we compared

hippocampus volumes and substantia alba hyperintensities
calculated from the MRI images of the patients at three
stages of AD and healthy control subjects utilizing volBrain
software.
AD is known to be more common among women than
in men. In the Baltimore Longitudinal Study, it was found
that AD incidence rates in women tended to be higher
than men [22] (1.43%/year vs. 1.12%/year). The generally
accepted women to men ratio is 2/1 [23]. In our study,
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women were in the majority among all patients with a
rate of 59.8%. These results indicate that our higher rate of
women diagnosed with AD is consistent with the studies
in the literature.
Although the risks of developing AD are multifactorial,
the most important risk factor is aging [24]. The incidence
of AD is directly related to age, and the incidence doubles
every 5 years after 65 years old. It has been estimated that
there were about 5.3 million AD patients in 2015 with 5.1
million being ≥65 years old and 200,000 people under
65 years old who had Early Onset AD (EOAD) [25,26].
In parallel with the literature, in our study, the mean age
was significantly increased in the patients at the advanced
stage compared to the patients at the other stages and the
control group.
In our study we compared volBrain measurement
results between the AD patients and control group.
Accordingly, the mean WhiMat, HipoT, HipoR, CerT,
CerTWM, CerR, CerRWM, CerL, CerLWM, Mesen,
CaudT, and AmygdT values were significantly increased
in the control group compared to the patients with AD
(for all p < 0.05). In the current study, volumetric values
were also compared between the AD stages. The mean
WhiMat, HipoR, HipoL, CerTWM, CerRWM, CerLWM,
and CreblR values were significantly higher in the early
stage compared to the advanced stage. Whereas, the
mean IC, GreyMat, HipoT, Bey, CerT, CerTGM, CerR,
CerRGM, CerL, CerLGM, and CreblR parameters were
significantly higher in the early stage compared to both
the moderate and advanced stages.
In a study by Laakso et al. (2000), changes in
hippocampus volumes over three years were evaluated in
patients with AD (n = 27) and healthy individuals (n =
8). In that study, the decrease in the hippocampus volume
was between 2.2% and 5.8%, in the control group and
between 2.3% and 15.6% in the AD patients. However,
no significant difference was found between the groups in
terms of the decreased rate of hippocampus volumes [27].
Using multiple regional cortical and subcortical
volumetric measurements produced by Freesurfer (51 in
total), the main purpose of this study was to elucidate the
results of these conformation approaches. MRI data were
analyzed from two large cohorts, the population-based
cohort (N = 406, all subjects 75 years old) and the AD
Neuroimaging Initiative cohort (N = 724). The ability of
the raw and adjusted hippocampal volumes to predict
diagnostic status was also evaluated. In both cohorts, raw
volumes correlated positively with intracranial volume.
The direction of correlation was reversed for all volume
intracranial fractions except lateral and third ventricles.
When comparing the estimation of the diagnostic
state using different approaches, small but important
differences were found. The choice of the normalization
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approach should be carefully considered when designing
a volumetric neuroimaging study [28].
In order to compare hippocampus volumes in different
dementia types, Vijayakumar (2012) evaluated MRI
images of patients with AD (n = 11), vascular dementia
(n = 10), mixed dementia (n = 3), normal pressure
hydrocephalus (n = 2), and healthy volunteers (n = 15)
using FLD3 procedure. The cognitive functions of the
participants were evaluated with MMSE. Hippocampus
volumes were found to be shrunk by 25% in AD, 21% in
the mixed dementia group, 11% in the vascular dementia
group, and 5% in the normal pressure hydrocephalus
group. According to the results of that study, hippocampus
volume decreases as the severity of dementia increases
[29]. In another study by Gerischer et al. (2018), MRI
images of AD patients (n = 21) and healthy individuals
(n = 21) were evaluated and hippocampus volumes and
viscosities of AD patients were found to be lower than
healthy individuals [30].
Coupe et al. (2019) evaluated age-related volume
changes in the brain in AD. Substantia alba, grey
matter, ventriculus lateralis, nucleus caudatus, nucleus
accumbens septi, corpus amygdaloideum, hippocampus,
putamen, globus pallidus, and thalamus volumes of 3262
AD patients and 2944 healthy volunteers were evaluated
using volBrain software. According to the study, the
reduction in the hippocampus volumes of the AD group
started 40 years before healthy volunteers, and the rate
of differentiation in ventriculus lateralis and amygdala
volumes followed the hippocampus [31].
In particular, the increase in the quality of imaging
methods in the recent period and developments in
information technologies and morphometric analysis
methods enable the provision of morphometric data
with more reliable and anatomical borders. With the data
obtained from reliable volumetric studies, it has become
possible to determine the interaction areas of intracranial
anatomical structures according to diseases and to
interpret the proportional results.
A second-order activation function is required in
individuals at risk for AD. Therefore, the existence of
an inverted U-shaped activation pattern is supported
[32] and suggests that hyperactivation may represent a
biomarker of early AD stages. Accordingly, quantitative
brain MRI volumes contribute to the diagnostic
identification of behavioral variant frontotemporal
dementia from early-onset AD [33]. Percentiles from an
MR-based volumetric quantification software program
can identify behavioral variant frontotemporal dementia
from EOAD. Hippocampal subfield volumes may also play
a key role in the diagnostic distinction. Also, large-scale
plasma proteomic profiling describes a high-performance
biomarker panel for AD screening and staging. This study
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comprehensively profiled the AD plasma proteome [34]. It
is said to serve as a basis for a high-performance, bloodbased test for clinical AD screening and staging.
As a limitation, the number of patients should be
increased. It is necessary to target specific molecules
that play a role in AD, such as acetylcholine, with animal
studies following imaging. The new clinical and preclinical
results to be obtained will increase the quality of the results
in this article. However, we believe that our findings could
provide contribution to the literature with using new
automatic systems to calculate volumetric values in AD
and similar neurodegenerative disorders.
In our study, when “volBrain Volumetry Reports” were
examined according to MMSE results, it was seen patients
who were at the same AD stage based on MMSE score
had different hippocampus volumes. We think that since
sometimes the MMSE score and the hippocampus volume
measurements do not match, the information about the
cognitive functions of the patient and the observations
and details about the daily life activities obtained from

the interviews with the patients and their relatives may be
more important in clinical staging.
5. Conclusion
We show that the most efficient study can be performed
by obtaining long-term periodic morphometric data of
an early diagnosed and regularly followed-up patient
population.
In future studies on AD and similar neurodegenerative
diseases, studying with this methodology will provide
healthier data, enabling a more efficient comparison
between different studies, contributing to developing
diagnostic criteria and treatment performance criteria for
AD and similar neurodegenerative diseases. Thus, it could
be possible to conduct morphometric analysis studies with
a high clinical value.
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